UOC
VERA icon

UBS O'Connor’s Vera Therapeutics VERA Stock Holding History

UBS O'Connor’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,000
Closed -$23K – 449
2025
Q2 		$23K Hold
40,000
– – ﹤0.01% 338
2025
Q1 		$103K Buy
40,000
+25,000
+167% +$803K ﹤0.01% 266
2024
Q4 		$36K Buy
+15,000
New +$664K ﹤0.01% 373
2024
Q2 		– Sell
-20,000
Closed -$97K – 636
2024
Q1 		$97K Buy
+20,000
New +$713K ﹤0.01% 425
2023
Q3 		– Sell
-55,000
Closed -$231K – 629
2023
Q2 		$231K Buy
+55,000
New +$497K ﹤0.01% 477

Other funds holding VERA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS O'Connor's VERA Position: Q3 2025 in Review

UBS O'Connor sold out of Vera Therapeutics (VERA) in Q3 2025, closing a stake of 27,400 shares — an estimated $646K sold.

UBS O'Connor first reported a position in VERA in Q1 2023 and held it in 10 quarters. The position peaked at $2.44M in Q3 2023. 175 funds tracked by Wall St. Rank hold VERA as of Q3 2025.

  • UBS O'Connor reported no remaining Vera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 27,400 Vera Therapeutics shares in Q3 2025, an estimated $646K.
  • UBS O'Connor first reported a position in Vera Therapeutics in Q1 2023 and held it in 10 quarters.
  • UBS O'Connor's Vera Therapeutics position peaked at $2.44M in Q3 2023.
  • 175 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.